Articles tagged "Immunosuppression"

2020 American Transplant Congress
Adult Primary Liver Transplant Recipient Outcomes by Immunosuppression Induction Received
T. Shaker¹, G. Larrieux¹, S. Jackson², S. Riad³, T. Pruett¹, T. Leventhal⁴
¹Surgery, Division of Transplantation, University of Minnesota, Minneapolis, MN, ²M Health Fairview, Minneapolis, MN, ³Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN, ⁴Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN
*Purpose: It has long been recognized that the highest risk of rejection of an organ is in the first few months post transplantation. To prevent…
2020 American Transplant Congress
Transplant Relevant MDSC Genetics: Differential Gene Expression Profiles of Immunosuppressive Myeloid-Derived Suppressor Cells Induced by Granulocyte-Colony Stimulating Factor
Y. S. Lee, J. S. Bromberg, J. R. Scalea
Department of Surgery, University of Maryland, Baltimore, MD
*Purpose: Myeloid-derived suppressor cells (MDSC) are expanded in inflammation conditions and can control alloreactive T cell responses. Granulocyte-colony stimulating factor (GCSF) is known to induce…
2020 American Transplant Congress
Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients
N. Nesselhauf¹, S. January¹, J. Hagopian¹, K. Progar¹, A. Khan²
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Surgery, Washington University School of Medicine, St. Louis, MO
*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…
2020 American Transplant Congress
Impact of Immunosuppression on Quality of Life among HLA-Identical Living Kidney Recipients at UCLA – A Qualitative Study
E. L. Wood¹, S. George², N. Kogut¹, E. Lum, MD³, J. L. Veale¹
¹Urology, UCLA, Los Angeles, CA, ²Fielding School of Public Health, UCLA, Los Angeles, CA, ³Medicine, Nephrology, UCLA, Los Angeles, CA
*Purpose: Tolerant kidney transplant recipients (off immunosuppression) report higher self-rated quality of life and a lower symptom burden compared to standard living recipients when using…
2020 American Transplant Congress
The Safety and Efficacy of 6-Month Steroid Reduction Strategy after Kidney Transplantation: A Prospective Cohort Study
J. Bang, C. Oh, S. Lee
Department of Surgery, Ajou University Medical School, Suwon, Korea, Republic of
*Purpose: In kidney transplantation, immunosuppressive regimens almost always contain corticosteroids for preventing acute rejection and graft loss. However, long-term maintenance of corticosteroids has been associated…
2020 American Transplant Congress
Early Tacrolimus-LCP Conversion Due to Adverse Effects in Pancreas Transplant Recipients Improves Tolerance But Not Graft Survival
J. L. Descourouez, M. R. Jorgenson, D. C. Felix, J. Wiegel, G. E. Leverson, D. A. Mandelbrot, R. R. Redfield, J. S. Odorico
UW Health, Madison, WI
*Purpose: Tacrolimus-LCP (LCPT) is an extended release formulation of tacrolimus which has been shown to have fewer adverse drug effects (ADE) than immediate release tacrolimus…
2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
2020 American Transplant Congress
Filgrastim Utilization Evaluation in Solid Organ Transplant Recipients
O. Witkowsky, L. Stanz, K. Schnelle
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Neutropenia occurs in up to 40% of kidney and liver transplant (txp) recipients and has been associated with higher mortality rates in liver txp.…
2020 American Transplant Congress
Belatacept Monthly Therapy: Transplant Recipients’ Experience
S. N. Little¹, É. N. Arsenault Knudsen², D. A. Mandelbrot¹
¹Transplant, University of Wisconsin Hospital and Clinics, Madison, WI, ²University of Wisconsin Hospital and Clinics, Madison, WI
*Purpose: While graft and patient outcomes with belatacept have been relatively well documented, the decision to use belatacept for kidney transplant recipients rests in part…
2020 American Transplant Congress
Belatacept versus Tacrolimus Combined with Antithymocyte Globulin in Kidney Transplantation
J. Goldman¹, A. Mitrokhin², B. Trivedi¹, V. Vidyasagar¹, N. Vadivel¹, N. Goes³, M. Hart¹
¹Swedish Medical Center, Seattle, WA, ²SUNY, Brooklyn, NY, ³Permanente Medical Group, Oakland, CA
*Purpose: Belatacept (BELA) used for maintenance immunosuppression (IS) after kidney transplant (KT) shows similar graft and patient survival, but improved allograft function, despite more rejection…